Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
73
PROK Quote, Financials, Valuation and Earnings
Last price:
$2.58
Seasonality move
:
5.06%
Day range:
$2.43 - $2.59
52-week range:
$0.46 - $7.13
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
451.44x
P/B ratio:
--
Volume:
409.3K
Avg. volume:
1.3M
1-year change:
44.38%
Market cap:
$363.8M
Revenue:
$76K
EPS (TTM):
-$0.54
Analysts' Opinion
-
Consensus RatingProKidney Corp. has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $6.50, ProKidney Corp. has an estimated upside of 152.92% from its current price of $2.57.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $1.00 representing 100% downside risk from its current price of $2.57.
Fair Value
-
According to the consensus of 7 analysts, ProKidney Corp. has 152.92% upside to fair value with a price target of $6.50 per share.
PROK vs. S&P 500
-
Over the past 5 trading days, ProKidney Corp. has overperformed the S&P 500 by 7.82% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
ProKidney Corp. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
ProKidney Corp. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter ProKidney Corp. reported revenues of $217K.
Earnings Growth
-
ProKidney Corp. has grown year-over-year earnings for 3 quarters straight. In the most recent quarter ProKidney Corp. reported earnings per share of -$0.12.
Enterprise value:
1.4B
EV / Invested capital:
4.41x
Price / LTM sales:
451.44x
EV / EBIT:
--
EV / Revenue:
1,912.15x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-9.70x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$4.9M
Return On Assets:
-38.9%
Net Income Margin (TTM):
-21403.63%
Return On Equity:
-42.51%
Return On Invested Capital:
-42.03%
Operating Margin:
-17759.91%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | $744K | -- | $217K | |
| Gross Profit | -$3.3M | -$4M | -$4.9M | -$1.2M | -$1.2M | |
| Operating Income | -$157.5M | -$156.3M | -$165.9M | -$49M | -$38.5M | |
| EBITDA | -$154.3M | -$152.3M | -$160.3M | -$47.8M | -$37.1M | |
| Diluted EPS | -$0.58 | -$0.56 | -$0.54 | -$0.14 | -$0.12 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.4M | $519.4M | $406.4M | $430.2M | $300M | |
| Total Assets | $251.4M | $532.4M | $451.8M | $474.8M | $351.6M | |
| Current Liabilities | $55.1K | $9.8M | $21M | $25.2M | $29.1M | |
| Total Liabilities | $7.8M | $11.9M | $23.6M | $31.3M | $33.3M | |
| Total Equity | $243.7M | $520.6M | $428.2M | $443.5M | $318.3M | |
| Total Debt | -- | $1.8M | $2.2M | $5.4M | $3.3M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$80.4M | -$127.6M | -$111.8M | -$29.2M | -$26.6M | |
| Cash From Investing | -$234.4M | -$90.5M | $91M | -$81.6M | $29M | |
| Cash From Financing | -$47K | $134.8M | $8.1M | $4.5M | $8M | |
| Free Cash Flow | -$113.4M | -$133.1M | -$146.7M | -$31.6M | -$31.8M | |
PROK
Sector
Market Cap
$363.8M
$28M
Price % of 52-Week High
36.05%
51.03%
Dividend Yield
0%
0%
Shareholder Yield
-2.31%
-1.54%
1-Year Price Total Return
44.38%
-17.48%
Beta (5-Year)
--
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$2.38
200-day SMA
Buy
Level
$1.96
Bollinger Bands (100)
Sell
Level
2.24 - 2.92
Chaikin Money Flow
Sell
Level
-152.4M
20-day SMA
Buy
Level
$2.32
Relative Strength Index (RSI14)
Buy
Level
57.03
ADX Line
Buy
Level
13.72
Williams %R
Sell
Level
-13.5593
50-day SMA
Sell
Level
$2.59
MACD (12, 26)
Sell
Level
-0.01
25-day Aroon Oscillator
Buy
Level
24
On Balance Volume
Neutral
Level
564.5M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-0.9511)
Sell
CA Score
(Annual)
Level (-15.7931)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (5.3463)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The firm focuses on the treatment of chronic kidney disease, shifting the emphasis away from management of kidney failure to the restoration of kidney function to stop or delay progression of CKD. It offers REACT, a product candidate that includes selected renal cells prepared from a patient's own, autologous, and renal cells. The company was founded on December 21, 2015 and is headquartered in Winston-Salem, NC.
Stock Forecast FAQ
In the current month, PROK has received 4 Buy ratings 3 Hold ratings, and 0 Sell ratings. The PROK average analyst price target in the past 3 months is $6.50.
-
Where Will ProKidney Corp. Stock Be In 1 Year?
According to analysts, the consensus estimate is that ProKidney Corp. share price will rise to $6.50 per share over the next 12 months.
-
What Do Analysts Say About ProKidney Corp.?
Analysts are divided on their view about ProKidney Corp. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that ProKidney Corp. is a Sell and believe this share price will drop from its current level to $1.00.
-
What Is ProKidney Corp.'s Price Target?
The price target for ProKidney Corp. over the next 1-year time period is forecast to be $6.50 according to 7 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is PROK A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for ProKidney Corp. is a Buy. 4 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of PROK?
You can purchase shares of ProKidney Corp. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase ProKidney Corp. shares.
-
What Is The ProKidney Corp. Share Price Today?
ProKidney Corp. was last trading at $2.58 per share. This represents the most recent stock quote for ProKidney Corp.. Yesterday, ProKidney Corp. closed at $2.57 per share.
-
How To Buy ProKidney Corp. Stock Online?
In order to purchase ProKidney Corp. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get PROK Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
PROK
Sector
P/E ratio
--
23.89x
PEG ratio
--
-0.01x
P/B ratio
--
1.82x
Price / LTM sales
451.44x
1.60x
Growth Metrics
PROK
Sector
Revenue growth
--
4.62%
Earnings growth
14.09%
10.88%
Revenue (5-year growth)
--
6.5%
Earnings forecast
-$0.14
-$0.21
Profitability
PROK
Sector
Profitability FY 2024
-$4.3M
$3.5M
Return on invested capital
-42.03%
-31.77%
Return on assets
-38.9%
-27.96%
Return on equity
-42.51%
-37.63%
Earnings Date
Last Earnings Date
Nov
10
Next Earnings Date
Mar
24
Estimated Next Earnings Date
Feb
9
Balance Sheet
PROK
Sector
Total cash
$271.7M
$26.3M
Short term investments
$259.2M
$25.7M
Total assets
$442.1M
$78M
Long term debt
$3.3M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
